Displaying drugs 13926 - 13950 of 14724 in total
Pipendoxifene
ER modulator, ERA-923(Pipendoxifene) is a estrogen receptor modulator being evaluated for the treatment of breast cancer. Pipendoxifene is a new 2-phenyl indole selective estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and was selected for further development as a treatment for metastatic breast cancer.
Investigational
Matched Description: … estrogen receptor modulators (SERM )that exhibits an excellent preclinical pharmacological profile and …
Efavaleukin alfa
Efavaleukin alfa is a fusion protein consisting of interleukin mutein fused to the C-terminus of an immunoglobulin G Fc domain by way of a G4S linker. It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With Steroid Refractory Chronic Graft Versus Host Disease).
Investigational
Matched Description: … It is under investigation in clinical trial NCT03422627 (Safety and Efficacy of AMG 592 in Subjects With …
Reproxalap
Reproxalap (previously ADX 102 or NS-2) is a small molecule inhibitor being developed by Aldeyra Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and Sjögren-Larsson syndrome. NS-2 has orphan drug status due to it being investigated for treatment of Sjogren-Larsson syndrome.
Investigational
Matched Description: … Therapeutics investigated against dry eye disease, allergic conjunctivitis, noninfectious anterior uveitis, and …
Giloralimab
Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 Is Administered in Combination With IV Modified FOLFIRINOX (Mffx) With or Without IV Budigalimab Compared to Mffx in Adult Participants With Untreated Pancreatic Cancer Metastasis).
Investigational
Matched Description: … Giloralimab is under investigation in clinical trial NCT04807972 (Study to Evaluate Adverse Events and …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and …
RUS 3108
RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories.
The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.
Investigational
Matched Description: … the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and …
3-hydroxyisoxazole-4-carboxylic acid
Experimental
3'-Deazo-Thiamin Diphosphate
Experimental
Cambendazole
Experimental
Vet approved
CRA_10991
Experimental
3h-Indole-5,6-Diol
Experimental
Xylose-derived lactam oxime
Experimental
3-Methylpyridine
Experimental
D-gluconhydroximo-1,5-lactam
Experimental
N-acetylserotonin
Experimental
Indole
Experimental
Zibotentan
Investigational
5-[2-(1H-pyrrol-1-yl)ethoxy]-1H-indole
Experimental
2-(3-METHYLPHENYL)-1H-INDOLE-5-CARBOXIMIDAMIDE
Experimental
Displaying drugs 13926 - 13950 of 14724 in total